Analyst Ratings For Pfizer Inc. (NYSE:PFE)
Today, Jefferies Financial Group set its price target on Pfizer Inc. (NYSE:PFE) to $39.00 per share.
There are 10 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Pfizer Inc. (NYSE:PFE) is Hold with a consensus target price of $40.4167 per share, a potential 2.74% upside.
Some recent analyst ratings include
- 7/31/2018-JPMorgan Chase & Co. Reiterated Rating of Buy.
- 7/19/2018-BMO Capital Markets Reiterated Rating of Buy.
- 6/11/2018-Morgan Stanley Reiterated Rating of Buy.
- 5/30/2018-Societe Generale Reiterated Rating of Neutral.
Recent Insider Trading Activity For Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (NYSE:PFE) has insider ownership of 0.06% and institutional ownership of 69.35%.
- On 7/20/2018 Sally Susman, Insider, sold 40,381 with an average share price of $37.22 per share and the total transaction amounting to $1,502,980.82.
- On 7/16/2018 Ian C Read, CEO, sold 486,753 with an average share price of $37.36 per share and the total transaction amounting to $18,185,092.08.
- On 6/6/2018 Laurie J Olson, EVP, sold 19,000 with an average share price of $36.45 per share and the total transaction amounting to $692,550.00.
- On 6/4/2018 W Don Cornwell, Director, sold 5,223 with an average share price of $36.40 per share and the total transaction amounting to $190,117.20.
- On 5/1/2018 Ian C Read, CEO, sold 132,312 with an average share price of $36.01 per share and the total transaction amounting to $4,764,555.12.
- On 3/13/2018 Douglas M Lankler, Insider, sold 50,000 with an average share price of $36.89 per share and the total transaction amounting to $1,844,500.00.
- On 3/13/2018 Rady A Johnson, EVP, sold 27,323 with an average share price of $36.55 per share and the total transaction amounting to $998,655.65.
About Pfizer Inc. (NYSE:PFE)
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Recent Trading Activity for Pfizer Inc. (NYSE:PFE)
Shares of Pfizer Inc. closed the previous trading session at 39,64 up +1,05 2,71 % with 38.21 shares trading hands.